Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Design Therapeutics, Inc. DSGN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
42/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$15.67
+22.9%

Design Therapeutics, Inc. (DSGN) is a Biotechnology company in the Healthcare sector, currently trading at $12.75. It has a SharesGrow Score of 41/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is DSGN = $16 (+22.9% upside).

Valuation: DSGN trades at a trailing Price-to-Earnings (P/E) of -10.2 (S&P 500 average ~25).

Net income is $70M (loss), growing at -9.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $645,000 against $213M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 17.14 (strong liquidity). Debt-to-assets is 0.3%. Total assets: $226M.

Analyst outlook: 3 / 6 analysts rate DSGN as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 46/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 58/100 (Partial), Income ?/100 (Fail).

$15.67
▲ 22.9% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for Design Therapeutics, Inc., the average price target is $15.67, with a high forecast of $18.00, and a low forecast of $14.00.
Highest Price Target
$18.00
Average Price Target
$15.67
Lowest Price Target
$14.00

DSGN SharesGrow Score Overview

51/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 46/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 58/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DSGN

~
VALUE Partial
46/100
DSGN trades at a trailing Price-to-Earnings (P/E) of -10.2 (S&P 500 average ~25). Forward PEG -0.5 — Peter Lynch undervalued (≤1.0). Trailing PEG 4.05. Analyst consensus target is $16, implying +25.5% from the current price $13. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
DSGN: +0%/yr revenue is, -9.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet DSGN: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 17.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
DSGN: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
58/100
Analyst outlook: 3 / 6 analysts rate DSGN as buy (50%). Analyst consensus target is $16 (+25.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.6-11.299
Volume427.79K
Avg Volume (30D)315.79K
Market Cap$786.32M
Beta (1Y)1.58
Share Statistics
EPS (TTM)-1.22
Shares Outstanding$57.33M
IPO Date2021-03-29
Employees56
CEOPratik Shah
Financial Highlights & Ratios
Gross Profit$-622K
EBITDA$-78.85M
Net Income$-69.79M
Operating Income$-79.47M
Total Cash$219.85M
Total Debt$645K
Net Debt$-16.21M
Total Assets$226.2M
Price / Earnings (P/E)-10.5
Analyst Forecast
1Y Price Target$15.00
Target High$18.00
Target Low$14.00
Upside+17.6%
Rating ConsensusBuy
Analysts Covering6
Buy 50% Hold 50% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS25056L1035

Price Chart

Track all markets on TradingView
DSGN
Design Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.60 52WK RANGE 11.30

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.54
-0.89%
 IMCR
IMCR
Immunocore Holdings plc
$31.64
-0.16%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.95
+4.18%
 IKNA
IKNA
Ikena Oncology, Inc.
$17.16
+1,152.55%
 ADCT
ADCT
ADC Therapeutics SA
$4.37
+13.21%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.89
+4.90%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message